Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Reducing pain associated with VLU debridement has the potential to indirectly improve healing rates as the more aggressive the debridement the faster the wound will heal

Wounds heal faster when debrided often by trained healthcare professionals. Published studies have shown that faster and more complete healing was achieved with more frequent debridement regardless of wound type, size or duration1,2. Weekly or even more frequent debridement resulted in shorter healing times compared with less frequent debridement. Education and training for proper debridement practices should not be limited to physicians but should include general staff members in order to make the flow of wound care more efficient. Nearly twice as many Venous Leg Ulcer’s and Diabetic Foot Ulcer’s healed completely with frequent debridement compared with those treated less frequently (50% v 28%).

The clinical professional has a range of options to achieve debridement and choice will depend on the pain threshold of the patient, type of necrotic tissue and where the patient is being treated. The fastest debridement procedure is sharp debridement usually associated with the use of a scalpel or similar instrument. The gentler approach such as the use of hydrogels may take weeks and many visits to facilitate dressing changes and re-application of the hydrogel and is costly and time consuming. Patients who undergo sharp debridement may feel greater pain than other approaches and this may impact on their compliance to undergo the necessary number of debridements to achieve an optimal wound bed that can start to progress towards healing. Also due to the level of procedural pain they may ask an immediate cessation of treatment at any stage during the process.

The need exists for not only a rapid approach to achieving pain relief immediately before the debridement procedure, but also the provision of sustained pain relief for some hours after completion. Research suggests that Medi-Solfen® offers these benefits and would provide increased compliance to achieve completion of the procedure and an increased willingness to return for future visits if required. The impact on the patient’s quality of life will be heightened if the stalled wound can be moved to an increased trajectory of healing faster. From a clinical perspective sharp debridement in pain free circumstances allows faster and more accurate removal of the appropriate amounts of dead tissue without interference from the patient asking to stop due to unbearable pain levels. Other pharmaceutical approaches to wound pain management can take up to 1 hour to attain the necessary level of anaesthesia prior to surgical intervention which adds to anxiety and stress for the patient anticipating what is coming next!

References

  1. Steed DL, Donohoe D, WebsterMW, Lindsley L (1996) Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J AmColl Surg; 183(1): 61-64.
  2. Wilcox JR, Carter MA and Covinton S (2013) Frequencies of debridement and time to heal. A retrospective cohort study of 312744 wounds. JAMA Dermatol; 149(9): 1050- 1058.